Page 92 - Innovation Delaware 2019

Regardless of a company’s size,
it’s likely that many use contractors. “Venture capital is telling companies: ‘Don’t invest in bricks and mortar. Invest in ideas,’” Cottone says.
Adesis, now a wholly owned subsidiary of Universal Display Corporation, is a contract research organization (CRO)
BIOSCIENCE
by the Numbers
$61
Million
The amount of venture capital investments in the state’s bioscience companies since 2014
No. 3
Delaware’s rank among the 50 states, based on bioscience- related patents per capita between 2014–2017
200,000
The square footage of the six-story $156 million Biopharmaceutical Innovation Building under construction on the University of Delaware’s STAR Campus
$104,000
Average annual wage for Delawareans working in the bioscience industry
8,000+
Individuals employed in Delaware’s bioscience industry
SOURCES: DELAWARE BIOSCIENCE ASSOCIATION, DELAWARE PROSPERITY PARTNERSHIP, TECONOMY, UNIVERSITY OF DELAWARE
HELEN STIMSON
THE RISE OF CONTRACT RESEARCH
ORGANIZATIONS
ANDREW COTTONE
the ImproJect Plunger for pre-filled syringes. The plunger is silicone-free, which eliminates silicone-induced aggregation and particulation to protect sensitive biologics.
In the future, Cottone predicts, drug discoveries will come from smaller companies. Consider that Kris Vaddi, formerly of Incyte, in 2016 founded Prelude Therapeutics to focus on treat- ments for cancers and rare diseases.
On the research side, a University of Delaware team led by Jason Gleghorn, assistant professor of biomedical engi- neering, recently developed a new method of growing blood vessels. The team em- bedded human blood-vessel cells in a gel made of collagen, a protein found in skin and joints. One day, these vessels could be used for tissue and organ transplantation.
90 DelawareBusinessTimes.com
RON DUBICK